Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Onorach Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Onorach Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Onorach Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Onorach Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Epirus Biopharma Raises US$36 Million In Series B Venture Financing 13
EPIRUS Biopharmaceuticals Secures USD5 Million in Venture Funding 15
EPIRUS Biopharmaceuticals Secures USD8.08 Million in Venture Funding 16
Private Equity 17
BioGeneration Ventures, Thuja Capital and Forbion Capital Partners Divest Bioceros 17
Partnerships 18
Polpharma Enters into Agreement with Epirus Biopharma 18
EPIRUS Biopharma Enters into Distribution Agreement with mAbxience 19
Epirus Enters Into Co-Development Agreement With Orygen Biotecnologia 20
Zalicus And Hydra Biosciences Enter Into Partnership To Develop Ion Channel Product Candidates For Treatment Of Pain 21
Licensing Agreements 22
Livzon Mabpharm Amends its Licensing Agreement with Epirus Biopharma 22
Zalicus Enters into Licensing Agreement with AnaBios for Sodium Channel Pain Modulation Program 24
Epirus Enters Into Licensing Agreement With Ranbaxy Labs For BOW015 25
Zalicus Extends Licensing Agreement With Novartis Institutes For Oncology Combinations 26
Bioceros Expands Licensing Agreement With Crucell 27
Zalicus Extends Licensing Agreement With Novartis Institutes for BioMedical Research 28
Equity Offering 29
Epirus Biopharma to Raise up to USD30 Million in Public Offering of Shares 29
Epirus Biopharma Raises USD53 Million in Public Offering of Shares 30
Zalicus Completes First Tranche Of Private Placement Of Shares For US$2 Million 31
Zalicus Completes Public Offering Of Shares For US$15 Million 32
Zalicus Completes Second Tranche Of Private Placement Of Shares For US$9 Million 33
Zalicus Completes Second Tranche Of Private Placement Of Shares For US$4.25 Million 34
Asset Transactions 35
Reliance Life Sciences Acquires Global Rights of Infliximab from EPIRUS Biopharma 35
Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus 36
Acquisition 37
Polpharma to Acquire EPIRUS Netherlands from EPIRUS Biopharma 37
Taro Pharma Acquires Zalicus Pharma 39
Epirus Biopharma Acquires Bioceros for USD14 Million 40
Epirus Biopharma Acquires Zalicus in Reverse Takeover Transaction 41
Onorach Ltd – Key Competitors 43
Onorach Ltd – Key Employees 44
Onorach Ltd – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46
Onorach Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Onorach Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Onorach Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Onorach Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Onorach Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Epirus Biopharma Raises US$36 Million In Series B Venture Financing 13
EPIRUS Biopharmaceuticals Secures USD5 Million in Venture Funding 15
EPIRUS Biopharmaceuticals Secures USD8.08 Million in Venture Funding 16
BioGeneration Ventures, Thuja Capital and Forbion Capital Partners Divest Bioceros 17
Polpharma Enters into Agreement with Epirus Biopharma 18
EPIRUS Biopharma Enters into Distribution Agreement with mAbxience 19
Epirus Enters Into Co-Development Agreement With Orygen Biotecnologia 20
Zalicus And Hydra Biosciences Enter Into Partnership To Develop Ion Channel Product Candidates For Treatment Of Pain 21
Livzon Mabpharm Amends its Licensing Agreement with Epirus Biopharma 22
Zalicus Enters into Licensing Agreement with AnaBios for Sodium Channel Pain Modulation Program 24
Epirus Enters Into Licensing Agreement With Ranbaxy Labs For BOW015 25
Zalicus Extends Licensing Agreement With Novartis Institutes For Oncology Combinations 26
Bioceros Expands Licensing Agreement With Crucell 27
Zalicus Extends Licensing Agreement With Novartis Institutes for BioMedical Research 28
Epirus Biopharma to Raise up to USD30 Million in Public Offering of Shares 29
Epirus Biopharma Raises USD53 Million in Public Offering of Shares 30
Zalicus Completes First Tranche Of Private Placement Of Shares For US$2 Million 31
Zalicus Completes Public Offering Of Shares For US$15 Million 32
Zalicus Completes Second Tranche Of Private Placement Of Shares For US$9 Million 33
Zalicus Completes Second Tranche Of Private Placement Of Shares For US$4.25 Million 34
Reliance Life Sciences Acquires Global Rights of Infliximab from EPIRUS Biopharma 35
Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus 36
Polpharma to Acquire EPIRUS Netherlands from EPIRUS Biopharma 37
Taro Pharma Acquires Zalicus Pharma 39
Epirus Biopharma Acquires Bioceros for USD14 Million 40
Epirus Biopharma Acquires Zalicus in Reverse Takeover Transaction 41
Onorach Ltd, Key Competitors 43
Onorach Ltd, Key Employees 44
Onorach Ltd, Subsidiaries 45